We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

Back to rankings

8 hedge funds and large institutions have $697K invested in Biostar Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more capital invested

Capital invested by funds: $203K → $697K (+$494K)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

33% more funds holding

Funds holding: 6 → 8 (+2)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$64.9K
2
Jane Street
Jane Street
New York
+$34.7K
3
UBS Group
UBS Group
Switzerland
+$8.55K
4
AIM
Acrospire Investment Management
Illinois
+$4.46K
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.45K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$1K
2
Morgan Stanley
Morgan Stanley
New York
-$9

BSPM Hedge Fund Activity: Q2 2016 in Review

8 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q2 2016, worth a combined $697K — up 243% from $203K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BSPM positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $64.9K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $1K sold.

  • 8 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q2 2016, up from 6 in Q1 2016.
  • Funds reported $697K of Biostar Pharmaceuticals, Inc. stock for Q2 2016, up 243% quarter-over-quarter.
  • 3 funds opened new Biostar Pharmaceuticals, Inc. positions in Q2 2016 and 1 closed out, a net change of +2 holders.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q2 2016 was Credit Suisse, an estimated $64.9K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q2 2016 was Tower Research Capital (TRC), an estimated $1K sold.

Based on aggregated 13F filings for Q2 2016.